

# MarÃ-a Isabel Lucena GonzÃ¡lez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2196569/publications.pdf>

Version: 2024-02-01

164  
papers

9,386  
citations

44069

48  
h-index

40979

93  
g-index

176  
all docs

176  
docs citations

176  
times ranked

6180  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Herbal and Dietary Supplements-Induced Liver Injury in Latin America: Experience From the LATINDILI Network. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e548-e563.                             | 4.4 | 21        |
| 2  | A revised electronic version of RUCAM for the diagnosis of DILI. <i>Hepatology</i> , 2022, 76, 18-31.   | 7.3 | 52        |
| 3  | Heterologous COVID-19 Vaccination in Spain: A Case Study of Individual Autonomy in the Real World. <i>Value in Health</i> , 2022, 25, 770-772.  | 0.3 | 5         |
| 4  | Reply. <i>Hepatology</i> , 2022, 76, E28-E28.   | 7.3 | 1         |
| 5  | Differential iNKT and T Cells Activation in Non-Alcoholic Fatty Liver Disease and Drug-Induced Liver Injury. <i>Biomedicines</i> , 2022, 10, 55.  | 3.2 | 4         |
| 6  | Reply. <i>Hepatology</i> , 2022, 76, E73-E73.   | 7.3 | 0         |
| 7  | Methionine Cycle Rewiring by Targeting miR-873-5p Modulates Ammonia Metabolism to Protect the Liver from Acetaminophen. <i>Antioxidants</i> , 2022, 11, 897.  | 5.1 | 3         |
| 8  | N-Acetylcysteine for the Management of Non-Acetaminophen Drug-Induced Liver Injury in Adults: A Systematic Review. <i>Frontiers in Pharmacology</i> , 2022, 13, .   | 3.5 | 18        |
| 9  | Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports. <i>Hepatology Communications</i> , 2022, 6, 1895-1909.                                       | 4.3 | 15        |
| 10 | Microbiota diversity in nonalcoholic fatty liver disease and in drug-induced liver injury. <i>Pharmacological Research</i> , 2022, 182, 106348.   | 7.1 | 29        |
| 11 | Profile of herbal and dietary supplements induced liver injury in Latin America: A systematic review of published reports. <i>Phytotherapy Research</i> , 2021, 35, 6-19.                                       | 5.8 | 13        |
| 12 | Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug Regimens. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1125-1135.                             | 4.7 | 31        |
| 13 | Clinical Characteristics and Outcome of Drug-Induced Liver Injury in the Older Patients: From the Young-Old to the Old-Old. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1147-1158.               | 4.7 | 16        |
| 14 | Genetic risk factors in the development of idiosyncratic drug-induced liver injury. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 153-169.  | 3.3 | 22        |
| 15 | Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials. <i>Pharmacological Research</i> , 2021, 164, 105404.                   | 7.1 | 29        |
| 16 | Characterizing Highly Cited Papers in Mass Cytometry through H-Classics. <i>Biology</i> , 2021, 10, 104.  | 2.8 | 6         |
| 17 | Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice. <i>Antioxidants</i> , 2021, 10, 390.  | 5.1 | 64        |
| 18 | Drug properties and host factors contribute to biochemical presentation of drug-induced liver injury: a prediction model from a machine learning approach. <i>Archives of Toxicology</i> , 2021, 95, 1793-1803. | 4.2 | 3         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | Serious liver injury induced by Nimesulide: an international collaborative study. Archives of Toxicology, 2021, 95, 1475-1487.   | 4.2  | 7         |
| 20 | Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. Journal of Hepatology, 2021, 75, 86-97.   | 3.7  | 72        |
| 21 | Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI. Journal of Hepatology, 2021, 75, 333-341.   | 3.7  | 23        |
| 22 | P041 Tandem mass tag-based quantitative proteomic profiling identifies novel putative serum biomarkers for the diagnosis of drug-induced liver injury in patients. , 2021, , .   |      | 1         |
| 23 | Lymphocyte Profile and Immune Checkpoint Expression in Drug-Induced Liver Injury: An Immunophenotyping Study. Clinical Pharmacology and Therapeutics, 2021, 110, 1604-1612.  | 4.7  | 15        |
| 24 | Advanced preclinical models for evaluation of drug-induced liver injury – consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET]. Journal of Hepatology, 2021, 75, 935-959.                   | 3.7  | 66        |
| 25 | Critical Review of Gaps in the Diagnosis and Management of Drug-Induced Liver Injury Associated with Severe Cutaneous Adverse Reactions. Journal of Clinical Medicine, 2021, 10, 5317.   | 2.4  | 3         |
| 26 | Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction. Acta Pharmaceutica Sinica B, 2021, 11, 3685-3726.  | 12.0 | 27        |
| 27 | Incidence and prevalence of acute hepatitis E virus infection in patients with suspected Drug-Induced Liver Injury in the Spanish DILI Registry. Liver International, 2020, 41, 1523-1531.                                       | 3.9  | 10        |
| 28 | Drug induced liver injury: an update. Archives of Toxicology, 2020, 94, 3381-3407.   | 4.2  | 125       |
| 29 | Drug-induced liver injury in older people. The Lancet Gastroenterology and Hepatology, 2020, 5, 862-874.   | 8.1  | 42        |
| 30 | Genome-Wide Association Study of Metamizole-Induced Agranulocytosis in European Populations. Genes, 2020, 11, 1275.  | 2.4  | 6         |
| 31 | Differential hepatoprotective role of the cannabinoid CB <sub>1</sub> and CB <sub>2</sub> receptors in paracetamol-induced liver injury. British Journal of Pharmacology, 2020, 177, 3309-3326.                                  | 5.4  | 13        |
| 32 | Systematic review: ibuprofen-induced liver injury. Alimentary Pharmacology and Therapeutics, 2020, 51, 603-611.  | 3.7  | 32        |
| 33 | Reply letter to “Editorial: bodybuilders beware”. Alimentary Pharmacology and Therapeutics, 2019, 50, 473-473.   | 3.7  | 0         |
| 34 | Endoplasmic Reticulum Stress-Induced Upregulation of STARD1 Promotes Acetaminophen-Induced Acute Liver Failure. Gastroenterology, 2019, 157, 552-568.  | 1.3  | 85        |
| 35 | FRI-077-Influence of drug categorization according to labelling information in the phenotypic presentation of drug-induced liver injury (DILI): An analysis in the Spanish DILI registry. Journal of Hepatology, 2019, 70, e418. | 3.7  | 1         |
| 36 | FRI-078-Serious liver injury induced by nimesulide: An international collaboration reporting 57 cases. Journal of Hepatology, 2019, 70, e418-e419.   | 3.7  | 0         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | Drug-induced liver injury. <i>Nature Reviews Disease Primers</i> , 2019, 5, 58.  | 30.5 | 409       |
| 38 | EASL Clinical Practice Guideline: Occupational liver diseases. <i>Journal of Hepatology</i> , 2019, 71, 1022-1037.   | 3.7  | 22        |
| 39 | Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 245-253.                                  | 4.7  | 58        |
| 40 | Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1028-1036.   | 4.7  | 52        |
| 41 | Assessment of Serious Acute and Chronic Idiosyncratic Drug-Induced Liver Injury in Clinical Practice. <i>Seminars in Liver Disease</i> , 2019, 39, 381-394.  | 3.6  | 20        |
| 42 | Deficient Endoplasmic Reticulum-Mitochondrial Phosphatidylserine Transfer Causes Liver Disease. <i>Cell</i> , 2019, 177, 881-895.e17.  | 28.9 | 209       |
| 43 | Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review. <i>United European Gastroenterology Journal</i> , 2019, 7, 825-837.                 | 3.8  | 29        |
| 44 | Next-Generation Sequencing of PTGS Genes Reveals an Increased Frequency of Non-synonymous Variants Among Patients With NSAID-Induced Liver Injury. <i>Frontiers in Genetics</i> , 2019, 10, 134.             | 2.3  | 10        |
| 45 | The usefulness of TV medical dramas for teaching clinical pharmacology: A content analysis of <i>House, M.D.</i> . <i>Educacion Medica</i> , 2019, 20, 295-303.  | 0.3  | 4         |
| 46 | When the Creation of a Consortium Provides Useful Answers: Experience of The Latin American DILI Network (LATINDILIN). <i>Clinical Liver Disease</i> , 2019, 13, 51-57.                                      | 2.1  | 21        |
| 47 | A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. <i>Gastroenterology</i> , 2019, 156, 1707-1716.e2.  | 1.3  | 97        |
| 48 | Drug-Induced liver Injury Associated with Severe Cutaneous Hypersensitivity Reactions: A Complex Entity in Need of a Multidisciplinary Approach. <i>Current Pharmaceutical Design</i> , 2019, 25, 3855-3871. | 1.9  | 13        |
| 49 | Hepatic Damage by Natural Remedies. <i>Seminars in Liver Disease</i> , 2018, 38, 021-040.  | 3.6  | 33        |
| 50 | Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1495-1502.  | 4.4  | 83        |
| 51 | Host Risk Modifiers in Idiosyncratic Drug-Induced Liver Injury (DILI) and Its Interplay with Drug Properties. <i>Methods in Pharmacology and Toxicology</i> , 2018, , 477-496.                               | 0.2  | 2         |
| 52 | Sulfasalazine-Induced Agranulocytosis Is Associated With the Human Leukocyte Antigen Locus. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 843-853.  | 4.7  | 18        |
| 53 | High Prevalence of Ibuprofen Drug-Induced Liver Injury in Spanish and Latin-American Registries. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 292-294.  | 4.4  | 18        |
| 54 | Idiosyncratic Drug-Induced Liver Injury: Mechanisms and Susceptibility Factors. , 2018, , 625-650.   |      | 0         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 55 | The influence of drug properties and host factors on delayed onset of symptoms in drug-induced liver injury. <i>Liver International</i> , 2018, 39, 401-410.   | 3.9  | 10        |
| 56 | Drug-induced liver injury: a safety review. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 795-804.  | 2.4  | 31        |
| 57 | DRESS cases included in the Spanish and Latin-American DILI registries: clinical phenotype and outcome. <i>Journal of Hepatology</i> , 2018, 68, S601.   | 3.7  | 3         |
| 58 | Data mining techniques to identify potential clinical presentation modulators in drug-induced liver injury. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO4-9-13. | 0.0  | 0         |
| 59 | A New Hepatoprotective Effect of Statins: Are They Always Safe for the Liver?. <i>American Journal of Gastroenterology</i> , 2017, 112, 384-385.   | 0.4  | 3         |
| 60 | Data Mining for Possible Drug-Host Interplay in Clinical Phenotypes of Drug-Induced Liver Injury. <i>Gastroenterology</i> , 2017, 152, S1080-S1081.  | 1.3  | 0         |
| 61 | Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. <i>Gastroenterology</i> , 2017, 152, 1078-1089.                   | 1.3  | 174       |
| 62 | Hepatotoxicity in Patients with Metabolic Syndrome: Causes and Consequences. <i>Current Hepatology Reports</i> , 2017, 16, 286-292.  | 0.9  | 3         |
| 63 | Jnk2 is indispensable in murine and human Ibuprofen-induced acute liver failure. <i>Journal of Hepatology</i> , 2017, 66, S400.  | 3.7  | 0         |
| 64 | Drug-induced liver and skin reactions: In need of a consensus definition. <i>Hepatology</i> , 2017, 65, 391-391.   | 7.3  | 3         |
| 65 | Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury. <i>Liver International</i> , 2017, 37, 132-140.   | 3.9  | 25        |
| 66 | The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury. <i>Nature Communications</i> , 2017, 8, 2068.   | 12.8 | 77        |
| 67 | Acetaminophen-Induced Liver Injury Alters the Acyl Ethanolamine-Based Anti-Inflammatory Signaling System in Liver. <i>Frontiers in Pharmacology</i> , 2017, 8, 705.  | 3.5  | 18        |
| 68 | A morphological method for ammonia detection in liver. <i>PLoS ONE</i> , 2017, 12, e0173914.   | 2.5  | 28        |
| 69 | The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative. <i>International Journal of Molecular Sciences</i> , 2016, 17, 313.  | 4.1  | 63        |
| 70 | Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury. <i>International Journal of Molecular Sciences</i> , 2016, 17, 714.  | 4.1  | 69        |
| 71 | Biomarkers in DILI: One More Step Forward. <i>Frontiers in Pharmacology</i> , 2016, 7, 267.  | 3.5  | 52        |
| 72 | Killer Immunoglobulin-Like Receptor Profiles Are not Associated with Risk of Amoxicillin-Clavulanate-Induced Liver Injury in Spanish Patients. <i>Frontiers in Pharmacology</i> , 2016, 7, 280.                      | 3.5  | 3         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 73 | Autoantibody presentation in drug-induced liver injury and idiopathic autoimmune hepatitis. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 414-422.  | 1.5  | 21        |
| 74 | Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid-responsive hepatitis: report of 22 cases. <i>Liver International</i> , 2016, 36, 302-310.   | 3.9  | 39        |
| 75 | Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. <i>Journal of Hepatology</i> , 2016, 65, 532-542.  | 3.7  | 115       |
| 76 | Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 507-516.  | 11.4 | 78        |
| 77 | Hepatotoxicity Associated with Non-Steroidal Anti-Inflammatory Drugs. A Comparative Analysis among Ibuprofen, Diclofenac and Nimesulide from the Spanish and Latin-American DILI Registries. <i>Journal of Hepatology</i> , 2016, 64, S239-S240. | 3.7  | 0         |
| 78 | Hepatotoxicity induced by coxibs: how concerned should we be?. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1463-1475.   | 2.4  | 26        |
| 79 | Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions. <i>Drug Safety</i> , 2016, 39, 925-943.   | 3.2  | 30        |
| 80 | Pro-Euro-DILI Registry: A Collaborative Effort to Enhance the Understanding of DILI. <i>Journal of Hepatology</i> , 2016, 64, S293-S294.   | 3.7  | 8         |
| 81 | “Drug-Induced Liver Injury Clinical Consortia: a global research response for a worldwide health challenge”. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 589-593.  | 3.3  | 17        |
| 82 | P1097 : Distinguishing drug induced autoimmune hepatitis from idiopathic autoimmune hepatitis. <i>Journal of Hepatology</i> , 2015, 62, S761.  | 3.7  | 1         |
| 83 | Hepatotoxicity related to Herbals and Dietary Supplements (HDS): a cause for concern. <i>Clinical Therapeutics</i> , 2015, 37, e123.   | 2.5  | 0         |
| 84 | Metabolic risk factors affect clinical Phenotype and outcome of Hepatotoxicity (DILI). <i>Clinical Therapeutics</i> , 2015, 37, e126-e127.   | 2.5  | 0         |
| 85 | Clinical Networks And Consortia In Drug-Induced Liver Injury (DILI): An Opportunity For Advancing Safety Science. <i>Clinical Therapeutics</i> , 2015, 37, e166.   | 2.5  | 0         |
| 86 | Reply. <i>Gastroenterology</i> , 2015, 148, 452-453.   | 1.3  | 0         |
| 87 | Acute liver failure following atorvastatin dose escalation: Is there a threshold dose for idiosyncratic hepatotoxicity?. <i>Journal of Hepatology</i> , 2015, 62, 751-752.   | 3.7  | 31        |
| 88 | Mitofusin 2 as a Driver That Controls Energy Metabolism and Insulin Signaling. <i>Antioxidants and Redox Signaling</i> , 2015, 22, 1020-1031.  | 5.4  | 69        |
| 89 | P1098 : Influence of metabolic risk factors in hepatotoxicity (DILI) phenotype and outcome. <i>Journal of Hepatology</i> , 2015, 62, S761-S762.  | 3.7  | 0         |
| 90 | Drug-induced liver injury: Interactions between drug properties and host factors. <i>Journal of Hepatology</i> , 2015, 63, 503-514.  | 3.7  | 319       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | The value of serum aspartate aminotransferase and gamma-glutamyl transpeptidase as biomarkers in hepatotoxicity. <i>Liver International</i> , 2015, 35, 2474-2482.   | 3.9 | 47        |
| 92  | Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 116-125.   | 3.7 | 95        |
| 93  | Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. <i>Annals of Hepatology</i> , 2014, 13, 231-239.  | 1.5 | 27        |
| 94  | Hepatotoxicity Induced by Herbal and Dietary Supplements. <i>Seminars in Liver Disease</i> , 2014, 34, 172-193.  | 3.6 | 77        |
| 95  | Reply. <i>Gastroenterology</i> , 2014, 147, 1442.  | 1.3 | 0         |
| 96  | Mechanisms of drug-induced liver injury. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2014, 14, 286-292.  | 2.3 | 86        |
| 97  | Use of Hy's Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients With Drug-Induced Liver Injury. <i>Gastroenterology</i> , 2014, 147, 109-118.e5.  | 1.3 | 248       |
| 98  | P310 ANABOLIC ANDROGENIC STEROIDS (AAS) ILLICIT USE IS A RAPIDLY GROWING CAUSE OF DRUG-INDUCED LIVER INJURY (DILI): A PROSPECTIVE SERIES FROM THE SPANISH-LATIN-AMERICAN DILI REGISTRY. <i>Journal of Hepatology</i> , 2014, 60, S169. | 3.7 | 0         |
| 99  | P309 PROGNOSTIC MODEL FOR PREDICTING DRUG-INDUCED ACUTE LIVER FAILURE. <i>Journal of Hepatology</i> , 2014, 60, S169.  | 3.7 | 0         |
| 100 | Selected ABCB1, ABCB4 and ABCC2 Polymorphisms Do Not Enhance the Risk of Drug-Induced Hepatotoxicity in a Spanish Cohort. <i>PLoS ONE</i> , 2014, 9, e94675.   | 2.5 | 19        |
| 101 | Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease. <i>World Journal of Hepatology</i> , 2014, 6, 160.  | 2.0 | 105       |
| 102 | Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports. <i>Annals of Hepatology</i> , 2014, 13, 231-9.  | 1.5 | 9         |
| 103 | Role of chemical structures and the 1331T>C bile salt export pump polymorphism in idiosyncratic drug-induced liver injury. <i>Liver International</i> , 2013, 33, 1378-1385.   | 3.9 | 38        |
| 104 | Use of Drugs Related to the Treatment of Diabetes Mellitus and Other Cardiovascular Risk Factors in the Spanish Population. The Di@bet.es Study. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 854-863.              | 0.6 | 5         |
| 105 | PP022-Variations in drug-induced liver injury (DILI) between different prospective dili registries. <i>Clinical Therapeutics</i> , 2013, 35, e24.  | 2.5 | 4         |
| 106 | PP025-Improving hy's law definition to better predict the risk of developing acute liver failure in drug-induced liver injury (DILI). <i>Clinical Therapeutics</i> , 2013, 35, e25.  | 2.5 | 0         |
| 107 | 518 THE SPANISH-LATIN AMERICAN DILI NETWORK: PRELIMINARY RESULTS FROM A COLLABORATIVE STRATEGIC INITIATIVE. <i>Journal of Hepatology</i> , 2013, 58, S212-S213.  | 3.7 | 4         |
| 108 | Causality Assessment. , 2013, , 287-302.   |     | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | HLA Alleles Influence the Clinical Signature of Amoxicillin-Clavulanate Hepatotoxicity. <i>PLoS ONE</i> , 2013, 8, e68111.  | 2.5 | 81        |
| 110 | Indacaterol-induced severe constipation and abdominal pain: is there a role for colonic $\alpha$ -adrenoceptors?. <i>BMJ Case Reports</i> , 2013, 2013, bcr2013009568-bcr2013009568.                                  | 0.5 | 3         |
| 111 | Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 784-795.   | 1.5 | 108       |
| 112 | Factores de riesgo y mecanismos de toxicidad hepática. Daño hepático inducido por medicamentos y tóxicos (excluido el alcohol). <i>Medicine</i> , 2012, 11, 573-580.  | 0.0 | 1         |
| 113 | Un caso de hepatopatía tóxica. <i>Medicine</i> , 2012, 11, 624.e1-624.e4.   | 0.0 | 0         |
| 114 | Trends in Qualifying Biomarkers in Drug Safety. Consensus of the 2011 Meeting of the Spanish Society of Clinical Pharmacology. <i>Frontiers in Pharmacology</i> , 2012, 3, 2.   | 3.5 | 11        |
| 115 | Genetic variations in drug-induced liver injury (DILI): resolving the puzzle. <i>Frontiers in Genetics</i> , 2012, 3, 253.  | 2.3 | 12        |
| 116 | Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain. <i>Frontiers in Genetics</i> , 2012, 3, 273. | 2.3 | 23        |
| 117 | Syndrome of inappropriate antidiuresis in doxylamine overdose. <i>BMJ Case Reports</i> , 2012, 2012, bcr-2012-007428-bcr-2012-007428.   | 0.5 | 7         |
| 118 | Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 817-828.   | 3.3 | 48        |
| 119 | Susceptibility to Amoxicillin-Clavulanate-Induced Liver Injury Is Influenced by Multiple HLA Class I and II Alleles. <i>Gastroenterology</i> , 2011, 141, 338-347.  | 1.3 | 412       |
| 120 | Recurrent Drug-Induced Liver Injury (DILI) with different drugs in the Spanish Registry: The dilemma of the relationship to autoimmune hepatitis. <i>Journal of Hepatology</i> , 2011, 55, 820-827.                   | 3.7 | 89        |
| 121 | Causality assessment methods in drug induced liver injury: Strengths and weaknesses. <i>Journal of Hepatology</i> , 2011, 55, 683-691.  | 3.7 | 164       |
| 122 | 486 IDIOSYNCRATIC DRUG-INDUCED LIVER INJURY (DILI) IN PATIENTS WITH PRE-EXISTING LIVER DISEASE: AN ANALYSIS OF THE CASES INCLUDED IN THE SPANISH DILI REGISTRY. <i>Journal of Hepatology</i> , 2011, 54, S199.        | 3.7 | 1         |
| 123 | Drug-Induced Autoimmune-Like Hepatitis: A Diagnostic Challenge. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2501-2503.   | 2.3 | 16        |
| 124 | Continuous reporting of new cases in Spain supports the relationship between Herbalife® products and liver injury. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1080-1087.                                 | 1.9 | 34        |
| 125 | The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. <i>Hepatology</i> , 2011, 54, 931-939.  | 7.3 | 279       |
| 126 | Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. <i>Hepatology</i> , 2010, 52, 303-312.  | 7.3 | 97        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 127 | Reflections on Running Training Workshops for Research Ethics Committee Members in Spain Between 2001 and 2008. <i>Croatian Medical Journal</i> , 2010, 51, 552-559.   | 0.7 | 3         |
| 128 | Antibiotic-Induced Liver Toxicity: Mechanisms, Clinical Features and Causality Assessment. <i>Current Drug Safety</i> , 2010, 5, 212-222.  | 0.6 | 34        |
| 129 | Drugs Associated with Hepatotoxicity and their Reporting Frequency of Liver Adverse Events in Vigibase. <i>Drug Safety</i> , 2010, 33, 503-522.  | 3.2 | 142       |
| 130 | 1137 THE HLA CLASS I B*1801 ALLELE INFLUENCES HEPATOCELLULAR EXPRESSION OF AMOXICILLIN-CLAVULANATE LIVER DAMAGE AND OUTCOME IN SPANISH PATIENTS. <i>Journal of Hepatology</i> , 2010, 52, S439.                              | 3.7 | 5         |
| 131 | Rechallenge in drug-induced liver injury: the attractive hazard. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 709-714.  | 2.4 | 47        |
| 132 | Fatal acute hepatitis after sequential treatment with levofloxacin, doxycycline, and naproxen in a patient presenting with acute <i>Mycoplasma pneumoniae</i> infection. <i>Clinical Therapeutics</i> , 2009, 31, 1014-1019. | 2.5 | 26        |
| 133 | Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex. <i>Hepatology</i> , 2009, 49, 2001-2009.   | 7.3 | 266       |
| 134 | Reply. <i>Hepatology</i> , 2009, 49, 1777-1779.  | 7.3 | 0         |
| 135 | Corrigendum to "Analysis of IL-10, IL-4 and TNF- $\alpha$ polymorphisms in drug-induced liver injury (DILI) and its outcome" [ <i>J Hepatol</i> 49 (2008) 107-114]. <i>Journal of Hepatology</i> , 2009, 50, 636.            | 3.7 | 1         |
| 136 | Drug-induced liver injury: insights from genetic studies. <i>Pharmacogenomics</i> , 2009, 10, 1467-1487.   | 1.3 | 90        |
| 137 | Pharmacogenomics in Drug Induced Liver Injury. <i>Current Drug Metabolism</i> , 2009, 10, 956-970.   | 1.2 | 70        |
| 138 | Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. <i>Hepatology</i> , 2008, 48, 588-596.  | 7.3 | 181       |
| 139 | Analysis of IL-10, IL-4 and TNF- $\alpha$ polymorphisms in drug-induced liver injury (DILI) and its outcome. <i>Journal of Hepatology</i> , 2008, 49, 107-114.   | 3.7 | 72        |
| 140 | Idiosyncratic drug hepatotoxicity: a 2008 update. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 261-276.  | 3.1 | 18        |
| 141 | Statins: Hepatic Disease and Hepatotoxicity Risk. <i>The Open Gastroenterology Journal</i> , 2008, 2, 18-23.   | 0.1 | 4         |
| 142 | Genetic and Molecular Factors in Drug-Induced Liver Injury: A Review. <i>Current Drug Safety</i> , 2007, 2, 97-112.  | 0.6 | 26        |
| 143 | Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). <i>British Journal of Pharmacology</i> , 2007, 150, 808-815.  | 5.4 | 44        |
| 144 | Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: A prospective series from Spain. <i>Hepatology</i> , 2006, 44, 850-856.   | 7.3 | 143       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 145 | Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. <i>Hepatology</i> , 2006, 44, 1581-1588.   | 7.3 | 267       |
| 146 | Prolonged cholestasis after raloxifene and fenofibrate interaction: A case report. <i>World Journal of Gastroenterology</i> , 2006, 12, 5244-6.  | 3.3 | 18        |
| 147 | The administration of N-acetylcysteine causes a decrease in prothrombin time in patients with paracetamol overdose but without evidence of liver impairment. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 59-63. | 1.6 | 16        |
| 148 | Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period. <i>Gastroenterology</i> , 2005, 129, 512-521.  | 1.3 | 847       |
| 149 | Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period. <i>Gastroenterology</i> , 2005, 129, 512-521.  | 1.3 | 595       |
| 150 | Is the Naranjo Probability Scale Accurate Enough to Ascertain Causality in Drug-Induced Hepatotoxicity?. <i>Annals of Pharmacotherapy</i> , 2004, 38, 1540-1541.   | 1.9 | 19        |
| 151 | HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. <i>Hepatology</i> , 2004, 39, 1603-1612.  | 7.3 | 134       |
| 152 | Causality assessment in drug-induced hepatotoxicity. <i>Expert Opinion on Drug Safety</i> , 2004, 3, 329-344.  | 2.4 | 70        |
| 153 | Drug use for non-hepatic associated conditions in patients with liver cirrhosis. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 71-76.   | 1.9 | 30        |
| 154 | Antidepressant-induced hepatotoxicity. <i>Expert Opinion on Drug Safety</i> , 2003, 2, 249-262.  | 2.4 | 75        |
| 155 | Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 887-890.          | 1.6 | 45        |
| 156 | Chronic Hepatitis C, Ibuprofen, and Liver Damage. <i>American Journal of Gastroenterology</i> , 2002, 97, 1854-1855.   | 0.4 | 19        |
| 157 | Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. <i>European Journal of Clinical Pharmacology</i> , 2002, 58, 435-440.  | 1.9 | 72        |
| 158 | Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2002, 40, 2-8.   | 0.6 | 92        |
| 159 | Comparison of two clinical scales for causality assessment in hepatotoxicity. <i>Hepatology</i> , 2001, 33, 123-130.   | 7.3 | 240       |
| 160 | Chronic liver injury related to use of benzazepam: an unusual instance of benzodiazepine hepatotoxicity. <i>Digestive Diseases and Sciences</i> , 2000, 45, 1400-1404.   | 2.3 | 28        |
| 161 | Trovafloxacin-Induced Acute Hepatitis. <i>Clinical Infectious Diseases</i> , 2000, 30, 400-401.  | 5.8 | 91        |
| 162 | Acute liver failure after treatment with nefazodone. <i>Digestive Diseases and Sciences</i> , 1999, 44, 2577-2579.   | 2.3 | 38        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 163 | Norfloxacin-Induced Cholestatic Jaundice. American Journal of Gastroenterology, 1998, 93, 2309-2311.  | 0.4 | 20        |
| 164 | Effect of cyclosporin a on platelet aggregation and thromboxane/prostacyclin balance in a model of extrahepatic cholestasis in the rat. Thrombosis Research, 1996, 81, 367-381. | 1.7 | 10        |